116 related articles for article (PubMed ID: 22853442)
1. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
J Med Econ; 2012; 15(6):1167-75. PubMed ID: 22853442
[TBL] [Abstract][Full Text] [Related]
2. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
Sail KR; Franzini L; Lairson DR; Du XL
Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
[TBL] [Abstract][Full Text] [Related]
5. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
8. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
9. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
10. Burden of breast cancer with brain metastasis: a French national hospital database analysis.
Benjamin L; Cotté FE; Mercier F; Vainchtock A; Vidal-Trécan G; Durand-Zaleski I
J Med Econ; 2012; 15(3):493-9. PubMed ID: 22304337
[TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant treatment of cancer of the breast: cost assessment of the protocol used].
Selke B; Bercez C; Lenne X; Bonneterre ME; Lebrun T; Bonneterre J
Bull Cancer; 1998 Nov; 85(11):961-6. PubMed ID: 9951423
[TBL] [Abstract][Full Text] [Related]
13. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
Görner M; Riemer-Hommel P
Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
[TBL] [Abstract][Full Text] [Related]
15. Economic outcomes of breast cancer survivorship: CALGB study 79804.
Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E
Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443
[TBL] [Abstract][Full Text] [Related]
16. The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis.
Mehra M; Hill K; Nicholl D; Schadrack J
J Med Econ; 2012; 15(2):245-52. PubMed ID: 22136441
[TBL] [Abstract][Full Text] [Related]
17. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Amonkar MM; Chastek B; Samant N; Teitelbaum A
J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
